Mutational Activation of the PI3K and RAS Pathways Is Mutually Exclusive in Human Breast Cancer Cell Lines
| Breast Cancer Cell Lines | PTEN | PIK3CA | KRAS | BRAF | HRAS | NRAS |
|---|---|---|---|---|---|---|
| BT549 | V275X | |||||
| CAMA-1 | D92H | |||||
| EVSA-T | T319X | |||||
| HCC1937 | no protein | |||||
| MDA-MB-415 | C136Y | |||||
| MDA-MB-468 | A72fsX5 | |||||
| ZR-75-1 | L108R | |||||
| MDA-MB-453 | E307K | H1047R | ||||
| BT20 | P539R/H1047R | |||||
| MDA-MB-361 | E545K/K567R | |||||
| BT474 | K111N | |||||
| BT483 | E542K | |||||
| MCF-7 | E545K | |||||
| OCUB-F | H1047R | |||||
| SK-BR-5 | H1047R | |||||
| SUM102PT | H1047R | |||||
| SUM185PE | H1047R | |||||
| SUM190PT | NA | H1047R | ||||
| T47D | H1047R | |||||
| UACC893 | H1047R | |||||
| SUM159PT | H1047L | G12D | ||||
| Hs578T | G12D | |||||
| SK-BR-7 | G12C | Q61R | ||||
| MDA-MB-134VI | G12R | |||||
| MPE600 | G12V | |||||
| SUM229PE | G12D | |||||
| MDA-MB-231 | G13D | G464V | ||||
| MDA-MB-435s | V600E | |||||
| DU4475 | V600E | |||||
| ZR-75-30 | I326T | |||||
| MDA-MB-157 | ||||||
| MDA-MB-175VII | ||||||
| MDA-MB-330 | ||||||
| MDA-MB-436 | ||||||
| SK-BR-3 | ||||||
| SUM149PT | ||||||
| SUM225CWN | NA | NA | ||||
| SUM1315MO2 | ||||||
| SUM52PE | ||||||
| UACC812 | ||||||
| Mutation rate | 8 of 38 (21%) | 14 of 39 (36%) | 5 of 40 (13%) | 4 of 40 (10%) | 2 of 40 (5%) | 1 of 40 (3%) |
NOTE: Overview of mutations that were identified in 40 human breast cancer cell lines. The mutations are detailed in Table 1.
Abbreviation: NA, not analyzed.